Keros Therapeutics (KROS) Payables (2019 - 2025)

Keros Therapeutics' Payables history runs 7 years deep, the most recent figure standing at $2.0 million for Q4 2025.

• Quarterly Payables fell 57.26% year-over-year to $2.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.0 million (down 57.26% YoY) and the FY2025 annual result came in at $2.0 million, down 57.26% from the prior year.
• Payables was $2.0 million for Q4 2025 at Keros Therapeutics, down from $2.3 million in the prior quarter.
• Across five years, Payables topped out at $7.7 million in Q2 2022 and bottomed at $1.4 million in Q2 2021.
• A 5-year average of $4.1 million and a median of $4.0 million in 2023 frame the typical range for Payables.
• Annual changes were most pronounced in 2021 — Payables tumbled 71.72% — and 2022, when it surged 458.31%.
• Keros Therapeutics' Payables stood at $3.6 million in 2021, then retreated by 8.4% to $3.3 million in 2022, then soared by 63.22% to $5.4 million in 2023, then declined by 15.56% to $4.6 million in 2024, then slumped by 57.26% to $2.0 million in 2025.
• Business Quant data shows KROS's Payables at $2.0 million in Q4 2025, $2.3 million in Q3 2025, and $5.3 million in Q2 2025.